Lupin (LUPIN) — Announcement

1 Announcement 🔴 High Importance Neutral 📄 PDF

Lupin Limited settled a patent infringement dispute with Astellas Pharma over its Mirabegron product. Under the settlement and license agreement, Lupin will pay USD 90 million (including a USD 75 million prepaid option payment) plus per-unit license fees through September 2027. The settlement resolves pending litigation and permits Lupin to continue selling Mirabegron.

2 Announcement Neutral 📄 PDF

Lupin Limited disclosed participation in the Dolat Capital Corporate Conference 2026 on February 18, 2026, an in-person group meet focused on decoding growth strategies. The event is subject to change at the company's or organizer's discretion. Any presentation will align with materials already available on company and stock exchange websites.

📊 Stock Analysis — LUPIN ✨ Ask AI About This

About Lupin Limited (LUPIN)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,04,071.47 Cr P/E: 36.2

View full LUPIN stock details →

📡 Get AI alerts when LUPIN files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track LUPIN — Free

💡 Ask AI about this filing

"How does this announcement affect Lupin Limited's outlook?" "What did Lupin Limited announce on 10 February 2026?" "Is this positive or negative for LUPIN?"

Ask AI Free →

📊 More LUPIN filings

See all LUPIN filings →

🔥 Also filed on 10 February 2026

APOLLOHOSP Apollo Hospitals Enterprise Limited Corporate Action APOLLOHOSP Apollo Hospitals Enterprise Limited Financial Results ZYDUSLIFE Zydus Lifesciences Limited Financial Results ZYDUSLIFE Zydus Lifesciences Limited Financial Results VBL Varun Beverages Limited Financial Results APOLLOHOSP Apollo Hospitals Enterprise Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when LUPIN files new disclosures

Track LUPIN filings, board meetings, and corporate actions. Free email alerts at 5 PM.